These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30920924)

  • 1. Treatment of Resistant and Refractory Hypertension.
    Acelajado MC; Hughes ZH; Oparil S; Calhoun DA
    Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on Refractory Hypertension.
    Matanes F; Khan MB; Siddiqui M; Dudenbostel T; Calhoun D; Oparil S
    Curr Hypertens Rep; 2022 Jul; 24(7):225-234. PubMed ID: 35384577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating essential hypertension. The first choice is usually a thiazide diuretic.
    Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.
    Calhoun DA
    J Clin Hypertens (Greenwich); 2007 Jan; 9(1 Suppl 1):19-24. PubMed ID: 17215651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistant hypertension and aldosterone: an update.
    Clark D; Ahmed MI; Calhoun DA
    Can J Cardiol; 2012 May; 28(3):318-25. PubMed ID: 22521297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
    Volpe M; Tocci G
    Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistant hypertension and aldosteronism.
    Pimenta E; Calhoun DA
    Curr Hypertens Rep; 2007 Nov; 9(5):353-9. PubMed ID: 18177580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory hypertension: definition, prevalence, and patient characteristics.
    Acelajado MC; Pisoni R; Dudenbostel T; Dell'Italia LJ; Cartmill F; Zhang B; Cofield SS; Oparil S; Calhoun DA
    J Clin Hypertens (Greenwich); 2012 Jan; 14(1):7-12. PubMed ID: 22235818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant hypertension: a review of diagnosis and management.
    Vongpatanasin W
    JAMA; 2014 Jun; 311(21):2216-24. PubMed ID: 24893089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistant hypertension and hyperaldosteronism.
    Gonzaga CC; Calhoun DA
    Curr Hypertens Rep; 2008 Dec; 10(6):496-503. PubMed ID: 18959838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.
    Glicklich D; Frishman WH
    Drugs; 2015 Apr; 75(5):473-85. PubMed ID: 25787734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory versus resistant hypertension.
    Siddiqui M; Calhoun DA
    Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):14-19. PubMed ID: 27798457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is resistant arterial hypertension?
    Shalaeva EV; Messerli FH
    Blood Press; 2023 Dec; 32(1):2185457. PubMed ID: 36891929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology].
    Denolle T; Chamontin B; Doll G; Fauvel JP; Girerd X; Herpin D; Vaïsse B; Villeneuve F; Halimi JM
    Presse Med; 2014 Dec; 43(12 Pt 1):1325-31. PubMed ID: 25459067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.